Detalhe da pesquisa
1.
Netrin-1 blockade inhibits tumour growth and EMT features in endometrial cancer.
Nature
; 620(7973): 409-416, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37532934
2.
Futibatinib for FGFR2-Rearranged Intrahepatic Cholangiocarcinoma.
N Engl J Med
; 388(3): 228-239, 2023 01 19.
Artigo
em Inglês
| MEDLINE | ID: mdl-36652354
3.
Lenvatinib plus pembrolizumab for patients with previously treated advanced ovarian cancer: Results from the phase 2 multicohort LEAP-005 study.
Gynecol Oncol
; 186: 182-190, 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38718741
4.
Qualitative evaluation of motives for acceptance or refusal of early palliative care in patients included in early-phase clinical trials in a French comprehensive cancer center: the PALPHA study.
Support Care Cancer
; 32(6): 353, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38748187
5.
Efficacy of Selpercatinib in RET Fusion-Positive Non-Small-Cell Lung Cancer.
N Engl J Med
; 383(9): 813-824, 2020 08 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32846060
6.
Safety, pharmacokinetic, pharmacodynamic and clinical activity of molibresib for the treatment of nuclear protein in testis carcinoma and other cancers: Results of a Phase I/II open-label, dose escalation study.
Int J Cancer
; 150(6): 993-1006, 2022 03 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-34724226
7.
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 71(2): 417-431, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34216247
8.
Pralsetinib for RET fusion-positive non-small-cell lung cancer (ARROW): a multi-cohort, open-label, phase 1/2 study.
Lancet Oncol
; 22(7): 959-969, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34118197
9.
Autophagy as a therapeutic target in pancreatic cancer.
Br J Cancer
; 124(2): 333-344, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32929194
10.
Pharmacokinetic-pharmacodynamic guided optimisation of dose and schedule of CGM097, an HDM2 inhibitor, in preclinical and clinical studies.
Br J Cancer
; 125(5): 687-698, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34140638
11.
A phase 1b study of the Notch inhibitor crenigacestat (LY3039478) in combination with other anticancer target agents (taladegib, LY3023414, or abemaciclib) in patients with advanced or metastatic solid tumors.
Invest New Drugs
; 39(4): 1089-1098, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33686452
12.
Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Lancet Oncol
; 21(7): 935-946, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32615108
13.
Phase I Study of Ramucirumab Plus Merestinib in Previously Treated Metastatic Colorectal Cancer: Safety, Preliminary Efficacy, and Pharmacokinetic Findings.
Oncologist
; 25(11): e1628-e1639, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32537847
14.
Phase 1 study of the MDM2 inhibitor AMG 232 in patients with advanced P53 wild-type solid tumors or multiple myeloma.
Invest New Drugs
; 38(3): 831-843, 2020 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-31359240
15.
Ramucirumab plus pembrolizumab in patients with previously treated advanced non-small-cell lung cancer, gastro-oesophageal cancer, or urothelial carcinomas (JVDF): a multicohort, non-randomised, open-label, phase 1a/b trial.
Lancet Oncol
; 20(8): 1109-1123, 2019 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-31301962
16.
External Beam Radiation Therapy for Resectable Soft Tissue Sarcoma: A Systematic Review and Meta-Analysis.
Ann Surg Oncol
; 25(3): 754-767, 2018 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-28895107
17.
Targeting apoptosis in acute myeloid leukaemia.
Br J Cancer
; 117(8): 1089-1098, 2017 Oct 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29017180
18.
Current Systemic Treatment Options for Tenosynovial Giant Cell Tumor/Pigmented Villonodular Synovitis: Targeting the CSF1/CSF1R Axis.
Curr Treat Options Oncol
; 17(2): 10, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26820289
19.
CSF1R inhibition with emactuzumab in locally advanced diffuse-type tenosynovial giant cell tumours of the soft tissue: a dose-escalation and dose-expansion phase 1 study.
Lancet Oncol
; 16(8): 949-56, 2015 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-26179200
20.
Xevinapant Combined with Pembrolizumab in Patients with Advanced, Pretreated, Colorectal and Pancreatic Cancer: Results of the Phase Ib/II CATRIPCA Trial.
Clin Cancer Res
; 30(10): 2111-2120, 2024 May 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-38502104